News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
FDA Issues Merck & Co., Inc. Warning for High Doses of Zocor
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Patients on the highest approved dose of the cholesterol-lowering drug Zocor may be at increased risk of muscle injury, U.S. regulators warned on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Regulatory
Merck & Co.
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Adcomms
Pfizer’s Talzenna Expansion Fails To Earn FDA Advisory Committee’s Support
May 22, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Moderna Shares Fall as Combo Flu/COVID-19 Vaccine Application Pulled
May 21, 2025
·
2 min read
·
Dan Samorodnitsky
Podcast
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
May 21, 2025
·
2 min read
·
Heather McKenzie
Opinion
Evolving Market Pressures Force Biopharma Companies to Cut Assets Early
May 21, 2025
·
5 min read
·
Michael N. Abrams
